Analysts Set Lyell Immunopharma, Inc. (NASDAQ:LYEL) Price Target at $43.00

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $43.20.

Several analysts have recently weighed in on LYEL shares. Zacks Research upgraded shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Friday, July 17th. Needham & Company LLC restated a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, June 9th.

Lyell Immunopharma Stock Down 0.5%

NASDAQ LYEL opened at $12.78 on Friday. The firm’s 50-day simple moving average is $14.25 and its two-hundred day simple moving average is $19.83. The company has a market cap of $313.11 million, a PE ratio of -0.93 and a beta of -0.06. Lyell Immunopharma has a 52 week low of $9.28 and a 52 week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. As a group, equities research analysts anticipate that Lyell Immunopharma will post -7.87 EPS for the current year.

Institutional Trading of Lyell Immunopharma

A number of institutional investors and hedge funds have recently bought and sold shares of LYEL. Bank of America Corp DE raised its position in Lyell Immunopharma by 314.2% in the 1st quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after buying an additional 25,276 shares during the last quarter. Renaissance Technologies LLC raised its stake in Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after acquiring an additional 76,921 shares during the period. Walleye Capital LLC purchased a new stake in Lyell Immunopharma in the 1st quarter worth $445,000. Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma during the first quarter worth about $959,000. Finally, Invesco Ltd. bought a new stake in shares of Lyell Immunopharma during the fourth quarter valued at approximately $3,036,000. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.